Hormonal Therapy and Endocrine Cancer Treatment Considerations

Hormonal Therapy and Endocrine Cancer Treatment Considerations

Hormonal therapy, also called endocrine therapy in many settings, is used for cancers whose growth is driven by hormones or hormone receptors. Breast and prostate cancers are common examples, but endocrine approaches may also appear in other disease-specific plans. These treatments may lower hormone levels, block receptors, suppress gonadal function, inhibit hormone synthesis, or interfere with downstream signaling. Because many hormonal therapies are taken at home for long periods, the RN's role includes education, adherence support, symptom assessment, and escalation of serious toxicity.

How Hormonal Therapy Works

Selective estrogen receptor modulators block or modify estrogen receptor activity in some tissues. Aromatase inhibitors reduce estrogen production in postmenopausal patients or in combination with ovarian suppression when ordered. Estrogen receptor downregulators degrade the receptor. Androgen deprivation therapy reduces testosterone signaling in prostate cancer through injections, surgery, receptor blockade, or androgen synthesis inhibition. Additional agents may be combined with endocrine therapy, including CDK inhibitors or targeted agents, which add separate monitoring needs.

Long-Term Adherence

A major challenge is that patients may not feel immediate benefit but may feel daily side effects. The nurse should normalize reporting symptoms without telling the patient to simply endure them. Ask how many doses were missed, what time of day the patient takes the medication, whether cost or refill delays exist, and whether side effects interfere with sleep, work, sexuality, or mood. Use nonjudgmental language because shame reduces accurate reporting. Missed-dose instructions should come from the label, oncology team, or pharmacist.

Bone, Cardiometabolic, and Sexual Health

Estrogen and androgen suppression can accelerate bone loss and increase fracture risk. Nurses reinforce ordered bone density testing, calcium and vitamin D discussions with the team, weight-bearing activity as tolerated, fall prevention, and dental evaluation when bone-modifying agents are part of the plan. Cardiometabolic effects may include weight change, lipid changes, insulin resistance, hypertension, or cardiovascular risk.

Sexual health concerns include vaginal dryness, dyspareunia, erectile dysfunction, decreased libido, infertility, and body image distress. The RN can assess, validate, provide basic education, and refer to oncology rehabilitation, sexual health, fertility, social work, or survivorship resources.

Serious Toxicities and Escalation

Some endocrine therapies increase risk for thromboembolism or stroke. Escalate unilateral leg swelling, chest pain, sudden shortness of breath, severe headache, vision changes, facial droop, or one-sided weakness. Other concerns include severe depression or suicidal thoughts, fracture symptoms, severe abdominal pain, jaundice, adrenal insufficiency symptoms with certain androgen synthesis inhibitors, and uncontrolled blood glucose. Injection-site reactions, missed appointments, and medication access problems also require follow-up because gaps can undermine the treatment plan.

Patient-Centered Education

Teach patients that hormonal therapy is active cancer treatment, not a supplement or optional maintenance pill. They should keep an updated medication list, report new prescriptions and supplements, and avoid stopping therapy without discussing symptoms with the oncology team. Many side effects can be managed, but the solution may require a drug holiday, switch, supportive medication, physical therapy, or specialty referral ordered by the provider. Encourage patients to track symptoms and bring specific examples to visits.

Practice Priorities

Endocrine side effects can sound minor in isolation but become treatment-limiting over time. Hot flashes that disrupt sleep, joint pain that limits walking, sexual pain that affects relationships, or mood changes that reduce motivation can all lead to missed doses. Nurses should assess patterns, not just presence or absence. Ask what the patient has stopped doing because of therapy. That question often reveals function, distress, and adherence risk better than a checklist. When symptoms are persistent, the nurse should connect the patient with the oncology team early instead of waiting for the patient to quit treatment silently.

• Ask directly about adherence and cost barriers.
• Include sexual health and mood in routine assessment.
• Connect long-term therapy with survivorship planning.
• Escalate vascular, neurologic, severe endocrine, and liver warning signs promptly.